Clinical trials: Age Related Maculopathy
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with…
- Trial name
- NCT01997164
- Testing
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal…
- Trial name
- HARRIER (NCT02434328)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Volunteers
- 1,048 people
- Sponsor
- Alcon Research
Macular Degeneration
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
- Trial name
- NCT02462486
- Testing
- Abicipar Pegol, Ranibizumab
- Where
- 187 sites in United States, Australia and 14 more
- Volunteers
- 949 people
- Sponsor
- Allergan
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Neovascular Age-related Macular Degeneration
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
This study was a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for…
- Trial name
- NCT04632056
- Testing
- Beovu
- Where
- 67 sites in Japan
- Volunteers
- 329 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.
- Trial name
- NCT04450329
- Testing
- SB15 (Proposed aflibercept biosimilar), Eylea (Aflibercept)
- Where
- 38 sites in United States, Croatia and 8 more
- Volunteers
- 449 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Macular Degeneration
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular…
- Trial name
- BURGUNDY (NCT04567303)
- Testing
- Zifibancimig, Ranibizumab, Port Delivery Platform
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 177 people
- Sponsor
- Hoffmann-La Roche
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Macular Edema, Macular Degeneration
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab…
- Trial name
- NCT02420132
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration
A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03539549
- Testing
- Abicipar pegol
- Where
- 37 sites in United States
- Volunteers
- 124 people
- Sponsor
- Allergan
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Visual Acuity, Geographic Atrophy
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
The purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual…
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Trial name
- NCT02895815
- Testing
- CNTO 2476 (6.0 * 10^4 cells), CNTO 2476 (3.0 * 10^5 cells)
- Sponsor
- Janssen Pharmaceutical K.K.
AMD
Post-Approval Study of the Implantable Miniature Telescope
The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal…
- Trial name
- PAS-01 (NCT01757132)
- Testing
- Implantable Miniature Telescope
- Where
- 16 sites in United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- VisionCare, Inc.
Age-related Macular Degeneration
QA102 Phase 1 Study in Healthy Young and Older Adult Subjects
This will be a double masked, randomized, placebo controlled, single and multiple oral dose study conducted in 3 parts. The safety and tolerability of single and multiple ascending oral doses of QA102 in healthy young and older…
- Trial name
- NCT04894071
- Testing
- QA102
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Smilebiotek Zhuhai Limited
Neovascular Age-related Macular Degeneration
A Study of IBI302 in Patients With nAMD
This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.
- Trial name
- NCT04820452
- Testing
- Low dose IBI302, High dose IBI302, Aflibercept
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Choroidal Neovascularization, Macular Degeneration
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
This is a prospective, observational, multi-center, study. The study will be conducted in approximately 12 ophthalmological clinics and practices throughout Greece.
- Trial name
- PERSEUS-GR (NCT02821247)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Greece
- Volunteers
- 119 people
- Sponsor
- Bayer
Age-Related (Dry) Macular Degeneration
Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration
Assess the effectiveness of externally applied micro current electrical stimulation on improving the ETDRS visual acuity in subjects with vision loss from dry age-related macular degeneration (AMD)
- Trial name
- NCT02540148
- Testing
- Nova Oculus™ Micro-current electrical stimulation
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- The Eye Machine Canada Inc.
Macular Degeneration
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related…
- Trial name
- NCT01482910
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 14 sites in China
- Volunteers
- 304 people
- Sponsor
- Bayer
Choroidal Neovascularization, Macular Degeneration
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple…
- Trial name
- RADICAL (NCT00492284)
- Testing
- verteporfin, ranibizumab, dexamethasone
- Where
- 26 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- QLT Inc.
Geographic Atrophy
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).
- Trial name
- ArMaDa (NCT06018558)
- Testing
- OCU410
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ocugen